Understand the source comparison
Summary comparison table
Compound Mechanism Muscle effect Key safety concern Status Soluble ActRIIB (ligand trap) Strong (+5.1% thigh volume) Vascular (BMP9/10) Discontinued 2013 ACE-083 Modified follistatin-Fc (local) Moderate (MRI increase) Lack of functional benefit Discontinued Bi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Compound
- Mechanism
- Muscle effect
- Key safety concern
- Status
- Soluble ActRIIB (ligand trap)
- Strong (+5.1% thigh volume)
- Vascular (BMP9/10)
- Discontinued 2013
- ACE-083
- Modified follistatin-Fc (local)
- Moderate (MRI increase)
- Lack of functional benefit
- Discontinued
- Bimagrumab
- ActRII/IIB antibody (receptor block)
- Moderate (+4.4% lean mass)
- Generally well-tolerated
- Active trials (metabolic)
- Glycoprotein (broad ligand trap)
- Moderate (~15% animal)
- Possible bone density loss
- Gene therapy trials
- MYO-029
- Anti-myostatin antibody
- Weak (no significant gains)
- Generally safe
- Discontinued (ineffective)
- Domagrozumab